The objective of this guideline is to provide healthcare professionals with pragmatic guidance on the management of patients with FVIII/FIX inhibitors although individual patient circumstances may dictate an alternative approach.
This document updates UK Haemophilia Centre Doctors Organization (UKHCDO) guidelines on the management of factor VIII/IX (FVIII/IX) inhibitors in congenital haemophilia (Hay et al, 2000, 2006). Acquired haemophilia is excluded and will be covered separately. Most data apply to FVIII inhibitors and the recommendations for FIX inhibitors are sometimes extrapolated from this. Low titre inhibitors are defined as <5 Bethesda units (BU)/ml and high titre ≥5 BU/ml. These guidelines are targeted towards haemophilia treaters in the UK. Not all recommendations may be appropriate for other countries with different health care arrangements and resources.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.